Milia-Argeiti E, Huet E, Labropoulou V T, Mourah S, Fenichel P, Karamanos N K, Menashi S, Theocharis A D
Department of Chemistry, Laboratory of Biochemistry, University of Patras, Greece.
Laboratoire CRRET, Université Paris-Est, CNRS, Créteil, France.
Int J Androl. 2012 Dec;35(6):835-844. doi: 10.1111/j.1365-2605.2012.01289.x. Epub 2012 Jun 19.
The histological classification of testicular germ cell tumours (TGCTs) to seminoma or non-seminomatous germ cell tumours is at present the main criterion for the clinical outcome and selection of the treatment strategy. In view of the need to identify novel prognostic biomarkers for TGCTs, we investigated the expression of the matrix metalloproteinases MMP-2 and MMP-9 in testicular tumour tissues and cell lines of both seminoma and non-seminoma origin. Immunohistochemistry and zymography analysis of tumoural tissues showed significantly higher levels of MMP-2 and MMP-9 compared with normal testis with the active forms detected only in the tumour tissues. Three cell lines representative of the different tumour types, JKT-1 seminoma, NCCIT teratocarcinoma and NTERA2/D1 embryonal carcinoma were also evaluated for their expression of these MMPs using qPCR and zymography and for their invasive properties. The more invasive non-seminomatous teratocarcinoma and embryonal cells expressed considerably more MMP-2 and MMP-9 compared with seminoma cells exhibiting lower invasiveness. Furthermore, an inverse relation was observed between invasiveness and the expression of endogenous inhibitors TIMP-1 and TIMP-2. The MMP inhibitor Marimastat inhibited invasion in all cell lines, the highest inhibition was observed in the more invasive NTERA2/D1 and NCCIT cells, which presented the highest ratio of MMP-2 and MMP-9 vs. TIMP-1 and TIMP-2. These results highlight the importance of MMP-2 and MMP-9 in the invasiveness of testicular tumours and suggest that their levels, vs. those of TIMP-1 and TIMP-2, may represent potential biomarkers for testicular malignancy.
睾丸生殖细胞肿瘤(TGCTs)组织学分类为精原细胞瘤或非精原细胞性生殖细胞肿瘤,目前是临床预后及治疗策略选择的主要标准。鉴于需要为TGCTs鉴定新的预后生物标志物,我们研究了基质金属蛋白酶MMP-2和MMP-9在精原细胞瘤和非精原细胞瘤起源的睾丸肿瘤组织及细胞系中的表达。肿瘤组织的免疫组织化学和酶谱分析显示,与正常睾丸相比,MMP-2和MMP-9水平显著更高,且仅在肿瘤组织中检测到活性形式。还使用定量聚合酶链反应(qPCR)和酶谱分析评估了代表不同肿瘤类型的三种细胞系JKT-1精原细胞瘤、NCCIT畸胎癌和NTERA2/D1胚胎癌中这些基质金属蛋白酶的表达及其侵袭特性。与侵袭性较低的精原细胞瘤细胞相比,侵袭性更强的非精原性畸胎癌和胚胎细胞表达的MMP-2和MMP-9要多得多。此外,观察到侵袭性与内源性抑制剂TIMP-1和TIMP-2的表达呈负相关。基质金属蛋白酶抑制剂马立马司他抑制了所有细胞系的侵袭,在侵袭性更强的NTERA2/D1和NCCIT细胞中观察到最高抑制率,这些细胞中MMP-2和MMP-9与TIMP-1和TIMP-2的比例最高。这些结果突出了MMP-2和MMP-9在睾丸肿瘤侵袭中的重要性,并表明它们与TIMP-1和TIMP-2相比的水平可能代表睾丸恶性肿瘤的潜在生物标志物。